I'm a board certified OBGYN. I've practiced for 20 years. Here's what's actually happening with mifepristone, because the coverage of it has been a mess.
On May 1, the 5th Circuit Court of Appeals ruled that the FDA overstepped its authority in 2023 when it eliminated the in-person dispensing requirement for mifepristone and allowed the drug to be mailed. On May 4, the Supreme Court issued a temporary administrative stay restoring mail-order access while it reviews the emergency appeals from Danco and GenBioPro. That stay expired May 11. We're waiting on the Court.
Let me say this clearly: I don't want mifepristone banned. Almost no OBGYN I know does. It has a legitimate place in our practice. What's being argued in Louisiana v. FDA is not whether the drug exists. It's whether the FDA's safety protocol "the REMS" should include the in-person dispensing safeguard the FDA itself required for the first 23 years this drug was on the market.
Here's what an in-person visit does that a telehealth call cannot:
1. It confirms gestational age by ultrasound. Patients are not always accurate about their dates. They are sometimes weeks off. Without imaging, no one knows.
2. It rules out ectopic pregnancy. Mifepristone does not treat an ectopic. If you take it and your pregnancy is in your fallopian tube, the tube will still rupture. Women die from this.
3. It creates a local physician who is accountable when something goes wrong — hemorrhage, sepsis, incomplete abortion requiring surgery. A doctor in another state on a video call cannot manage a bleeding patient at 2 a.m.
The 2023 REMS change removed all three. And here is the part the mainstream media will not tell you: it is entirely predictable that a partner, a parent, or a boyfriend will substitute themselves on the telehealth visit to spare the patient an awkward conversation. That means the person actually taking the drug may never be seen, never be examined, and never have her dates verified. If she is further along than she said, the outcome can be a severely preterm infant. This is a child who may live decades with profound disability, at a public cost in the tens of millions of dollars over a lifetime.
This is why the FDA itself opened a safety review in September 2025. Real-world claims data is suggesting complication rates well above what is on the drug label. Secretary Kennedy and Commissioner Makary launched that review for a reason. Until it's finished, returning to in-person dispensing is the conservative clinical position. And by "conservative" I mean cautious. Careful. The standard of care.
The Fifth Circuit didn't ban anything. It restored the same safeguard the FDA enforced under Clinton, Bush, Obama, and the first Trump administration. That's not extremism. That's medicine.